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Current strategies for early detection of breast and other cancers
are limited in part because some lesions identified as potentially
malignant do not develop into aggressive tumors. Acid pH has
been suggested as a key characteristic of aggressive tumors that
might distinguish aggressive lesions from more indolent pathol-
ogy. We therefore investigated the novel class of molecules, pH
low insertion peptides (pHLIPs), as markers of low pH in tumor
allografts and of malignant lesions in a mouse model of sponta-
neous breast cancer, BALB/neu-T. pHLIP Variant 3 (Var3) conju-
gated with fluorescent Alexa546 was shown to insert into tumor
spheroids in a sequence-specific manner. Its signal reflected pH in
murine tumors. It was induced by carbonic anhydrase IX (CAIX)
overexpression and inhibited by acetazolamide (AZA) administra-
tion. By using 31P magnetic resonance spectroscopy (MRS), we
demonstrated that pHLIP Var3 was retained in tumors of pH equal
to or less than 6.7 but not in tissues of higher pH. In BALB/neu-T
mice at different stages of the disease, the fluorescent signal from
pHLIP Var3 marked cancerous lesions with a very low false-posi-
tive rate. However, only ∼60% of the smallest lesions retained a
pHLIP Var3 signal, suggesting heterogeneity in pH. Taken to-
gether, these results show that pHLIP can identify regions of low-
er pH, allowing for its development as a theranostic tool for
clinical applications.
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The reprogramming of metabolism resulting in enhanced gly-colysis is now a well-recognized characteristic of many can-
cers. Increased levels of glycolysis—while contributing to energy
generation—are essential to supply carbon backbones for the
synthesis of the nucleotides required to sustain DNA synthesis
under conditions of abnormal proliferation (1, 2). Thus, the well-
recognized Warburg effect plays a physiological role in sustain-
ing the malignant phenotype. In addition to the requirement for
nucleotide synthesis, glycolysis can be essential for energetics
under hypoxia. Because a poor vascular supply is also charac-
teristic of cancers, hypoxia generated by poor perfusion is now
regarded as a hallmark of cancer (3). This hypoxia, if sufficiently
extreme, may dictate that cancer cells as well as macrophages
and other stromal cells in the hypoxic microenvironment use
glycolysis to maintain bioenergetics. It has recently been estab-
lished that endothelial cells participating in sprouting angio-
genesis rely on glycolysis for their energy requirements (4).
Furthermore, many of the most prevalent and well-known on-
cogenic signaling pathways such as myc and PI3K redirect the
cancer cell metabolism toward increased glycolysis (1, 2). Thus,
levels of glycolysis greater than those found in normal tissues are
associated with malignancy.
One consequence of glycolysis is the production and secretion
of lactate, resulting in decreased extracellular pH (5, 6). In addi-
tion, cancer cells and especially hypoxic cancer cells express car-
bonic anhydrases IX and XII (7, 8), which catalyze the formation
of extracellular acid from carbon dioxide and thus enhance acidic
extracellular pH (9). Extracellular acidity as evoked by tumor
progression has the potential to regulate multiple biological pro-
cesses such as proliferation, angiogenesis, immunosuppression,
invasion, and chemoresistance (5, 10–16). Exposure of cancer cell
lines to acidic pH (6.8) increased migration and invasion in vitro
(17) and in vivo (18). Acidic pH induces increased expression and
release of MMP-9 (19) and MMP-2 (18). Reduction of tumor pH
by oral bicarbonate treatment reduced metastasis in vivo in xe-
nografts (20). Thus, alterations in extracellular pH are charac-
teristic of cancer and are thought to contribute to aspects of the
malignant phenotype and to resistance to some forms of therapy.
Cancer rarely arises in a single step but instead represents a
series of genetic alterations, eventually leading to fully formed
tumors. At the pathological level, this can be seen as lesions first
showing hyperproliferation, and dysplasia followed by invasion.
This process can be accelerated in mice bearing transgenes that
already have genetic alterations that predispose them to cancer.
Accordingly, we wished to ask whether detection of acid pH in a
tumor might be a useful biomarker for detection of early neoplasia.
Because the extracellular pH in tumors is just 0.5–1 pH units
lower than the extracellular pH in normal tissue, it has proven
challenging to design molecular probes sensitive to this differ-
ence. Several magnetic resonance (MR)-based approaches to
measure tumor acidity have been developed (21), all with some
significant limitations in regards to translation to the clinic. Al-
though a number of pH-sensitive tumor-targeting agents have
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been recently introduced (22, 23), the challenge has been to
achieve fast pH transition within a single pH unit, to discriminate
healthy tissue of normal pH from the more acidic environment
of tumors.
A novel class of molecules that target areas of low pH has re-
cently been developed: the pH low insertion peptides (pHLIPs)
(24). The mechanism of pHLIP-mediated targeting is based on
pH-dependent membrane-associated folding into a coil confor-
mation, which releases free energy (25). This coil inserts into cell
membranes and thus allows selective targeting of cancerous tissue
of low extracellular pH (pH 6.0–6.8) while avoiding retention in
healthy tissue (pH 7.2–7.4). WT-pHLIP has been successfully
tested in vitro as an agent for intracellular delivery of large polar
cargo molecules (26–29). In addition, WT-pHLIP promotes pH-
dependent fusion of pHLIP-coated liposomes containing grami-
cidin channels with cellular membranes, thus destroying the bal-
ance of monovalent ions (30).
In vivo, pHLIP has been used as a marker in mouse models of
cancer (31–38), ischemia (39), arthritis (33), and influenza (40).
It also has been used to target various nanoparticles (41, 42) (43)
and liposomes (39, 44) to acidic tissue. Studies differ as to whether
the actual pH was determined by 31P magnetic resonance spec-
troscopy (MRS) (32, 34, 38) or other methods (45). Tumor pH
alteration has been attempted by bicarbonate (34) or carbonic
anhydrase IX (CAIX) overexpression (38), and the effect on
pHLIP uptake has been registered.
Clinical applications have focused on the topical application of
pHLIP onto biopsies from human head and neck cancer patients,
where pHLIP detected cancerous tissue within the samples (46, 47).
However, no systematic assessment of the degree of pHLIP
labeling in regard to pathological findings had been undertaken,
which is now the main focus of our study. Most of the examples
above used WT-pHLIP for their studies. We compared uptake
with pHLIP Variant 3 (Var3) and Var7, as these had previously
been selected among 16 rationally designed pHLIP variants as
the best potential tumor-targeting pHLIPs (24). These data led
us to concentrate our efforts on pHLIP Var3, recently in-
troduced as an optimized tumor-targeting pHLIP (24), to cor-
relate its tumor uptake and retention with (i) tumor pH and (ii)
manipulation of extracellular pH by CAIX overexpression and
inhibition through acetazolamide (AZA) and (iii) evaluate Var3
use under “clinical” conditions for targeting of early and de-
veloped lesions using the spontaneous breast cancer model
BALB/neu-T (48) as it progresses from atypical hyperplasia to
invasive carcinomas.
Results
First we used 4T1 breast cancer cells, which closely mimic triple-
negative human breast cancer, grown as allografts in BALB/c
mice to assess targeting and retention of fluorescent pHLIPs.
pHLIP variants Var3 and Var7 (Table 1) and their corresponding
nontargeting K-pHLIP controls, all conjugated with Alexa546,
were administered by tail vein injection once 4T1 tumors reached
5 mm in geometric mean diameter (GMD; Fig. 1A). Increased
fluorescence in the tumors was observed 1 h after injection, with
a further increase of the signal over 5 h (Fig. 1 B and C).
Fluorescence still persisted after 24 h. pHLIP Var3 had en-
hanced tumor targeting and greater retention than pHLIP Var7.
To account for irregular tumor vasculature as a possible cause
for pHLIP retention, we compared pHLIP Var3 and Var7 to
their noninserting counterparts K-Var3 and K-Var7 (Table 1).
Although injection of the K-pHLIPs led to an increase in fluo-
rescence above background over 24 h (∼250%), fluorescence
from pHLIP Var3 and Var7 was 5–10-fold as high, indicating a
significant contribution of low pH targeting. Because pHLIP
Var3 showed the most persistent fluorescence signal and re-
tention, further experiments were conducted with pHLIP Var3.
Using spheroids as a tissue culture 3D model for tumors, the
uptake of pHLIP Var3 and of the K-pHLIP noninserting control
peptide was compared between spheroids with different levels of
extracellular acidity. We used the cell line HCT116, reported
both to have low expression of CAIX and to readily form
spheroids (8), and HCT116 transduced to overexpress CAIX,
leading to acidification of the extracellular space (8) (Fig. 2 A and
B). As expected, the CAIX-overexpressing spheroids, generating
more acid, grew faster than the empty vector (EV) controls (Fig.
S1A) and were targeted by pHLIP Var3 better than EV spher-
oids. We also compared the K-pHLIP Var3 control with pHLIP
Var3 within the same spheroid by tagging them to different
fluorochromes (Var3-Alexa546 and K-Var3–Alexa647; Fig. 2C).
pHLIP Var3 was detected throughout the spheroid, whereas
K-pHLIP Var3 remained on the outside. Thus, the uptake and re-
tention of pHLIP Var3 was sequence-specific and pH-responsive.
Next, we tested whether pHLIP Var3 retention in tumors in
vivo was altered by CAIX overexpression (Fig. 3). As reported
(8), the growth rate of tumors from CAIX-overexpressing cells
(HCT116 CAIX) was greater than that of the controls (HCT116
EV; Fig. 3A). We normalized the fluorescence of pHLIP Var3 to
tumor volume. The CAIX-overexpressing tumors (Fig. S1B) had
a significantly higher uptake of pHLIP Var3 than the controls at
both 5 h and 18 h (Fig. 3B). To establish that pHLIP Var3 up-
take by tumors reflected extracellular acid pH, we asked whether
inhibition of CAIX activity by AZA (49) would reduce uptake or
retention of Var3 within tumors. We injected mice bearing 4T1
tumors with AZA (40 mg/kg, i.p.) followed by injection of pHLIP
Var3 24 h later (Fig. 3C). The fluorescence signal from the
pHLIP Var3 probe was monitored over another 24 h. The mice
treated with AZA showed a significantly greater decline in the
fluorescence signal compared with untreated controls. This in-
dicates that pHLIP Var3 retention indeed correlates with the
extracellular pH of tumors, that changes in tumor pH will be
Table 1. The amino acid sequence of the pHLIP variants and
K-pHLIP controls






The transmembrane protonatable D and E (underlined) residues in Var3
and Var7 were replaced by positively-charged K residues (also underlined) in
K-Var3 and K-Var7, which prevents K-Var insertion into membrane and thus
tumor targeting.
Fig. 1. Comparison of uptake and retention of pHLIP variants in vivo. Tu-
mors from the 4T1 cell line were grown in syngeneic BALB/c mice. Once the
tumors reached a GMD of 5 mm, different pHLIP variants (n = 5 per group)
were injected intravenously. Fluorescence was normalized to the initial sig-
nal before pHLIP injection. (A) Tumor growth with time after inoculation.
Uptake of pHLIPs Var3 and (B) K-Var3 Var7 and K-Var7 (C) followed by in
vivo fluorescence over time (data are mean ± SEM).











reflected by changes in pHLIP Var3 signal, and that protein
levels of CAIX do not directly affect pHLIP Var3 retention.
Finally, we attempted to establish a direct correlation of actual
pH within the tumor to pHLIP Var3 uptake and retention in
vivo. To determine the pH of tumors, we used the 31PMRSmethod
(50). We used inorganic phosphate, phosphocreatine (PCr), and
ATP to calculate the overall pH from MRS spectra (Table S1).
According to the literature, approx. 70% of the signal in bulk pH
measurement is from intracellular sources and 30% from extra-
cellular ones. Hence, a large enough difference in extracellular
pH would still be reflected in the signal (50–52). To avoid con-
tamination of the signals, localized voxels of >125 mm3 were
used rather than global scans, which meant that we could not
compare the tumors to normal mammary glands, which are too
small in volume. Thus, we compared the pH and pHLIP Var3
fluorescence detected in tumors to muscle (Fig. 4). Although
muscle showed an overall pH of 7.1 ± 0.1 (n = 3) and no fluo-
rescence signal above background levels, the pH measured in
tumors of the same animal was lower at 6.7 ± 0.0 (n = 3), with a
fluorescent signal over background ∼5.5 times higher than in
background and 4.2 times higher than in muscle. The measured
values represent bulk pH, with the pH at the surface of glycolytic
cancer cells expected to be lower (53).
Our data clearly indicate correlations between tissue pH and
pHLIP Var3 uptake and retention in vivo, raising questions of
whether changes in pHmight occur in early neoplasia and whether
pHLIP Var3 will be able to reflect these changes. To examine
early lesions, we used the transgenic BALB/neu-T model of breast
cancer (48). These mice develop atypical mammary hyperplasia by
week 9–10 of age, carcinoma in situ and invasive carcinoma
around week 15, and palpable tumors between week 20 and 30.
In our experiments, mice aged between 124 d and 151 d showed
histological evidence of cancer and precursor hyperplasia. Be-
cause these lesions were relatively small, we could not detect the
fluorescence after i.v. injection of pHLIP Var3 by whole animal
imaging; we could, however, reveal a signal after sacrifice and
dissection (Fig. 5). We also examined older mice with palpable
tumors. Eight breasts per animal were examined and dissected
from each mouse, with a total of 164 samples taken. Histological
sections from each breast were scored for the presence of hy-
perplasia, invasive carcinoma, necrosis, and whether any normal
tissue was still retained within the sample. For each of these
characteristics, we plotted a receiver–operator curve (ROC) of
sensitivity versus specificity (Fig. 6). The fluorescent signal from
the pHLIP Var3 peptide showed the highest sensitivity and
specificity with regard to the presence or absence of invasive
carcinoma, with an area under the ROC curve of 0.939 ± 0.028
SEM (Fig. 6A and Tables S2 and S3); less so for the presence of
necrosis, with an area under the ROC curve of 0.860 ± 0.033
SEM (Fig. 6B and Tables S4 and S5); and less again for the
retention of any normal tissue within the tumor, with an area
under the ROC curve of 0.789 ± 0.041 SEM (Fig. 6C and Tables
S6 and S7). We had wondered whether pHLIP Var3 retention
was due to necrosis but found the correlation weaker than the
correlation with carcinoma, confirming earlier findings that
pHLIP Var3 did not target necrotic cores (54). Furthermore, we
did not observe any signal in tissues without invasive carcinoma.
We did not find any breasts with hyperplasia but without invasive
cancer. Thus, there were no false-positives within our sample size
(Table S2). Although large carcinomas (>5 mm GMD) were all
positive for uptake, among the small but histological carcinomas,
the results were variable. Fifty-seven percent of these were
positive, an indication of a significant false-negative rate for early
neoplastic lesions as assessed by pHLIP Var3.
Discussion
In this study we explored the feasibility of using the pHLIP Var3
peptide as a biomarker for detection of early neoplasia. Our data
indicating that pHLIP Var3 exhibits tumor targeting and re-
tention are in good accordance with previous findings with other
Fig. 2. The ability of pHLIP to penetrate the spheroid is sequence specific. (A and B) Following incubation with fluorescent pHLIP Var3 for 6 h, pHLIP
fluorescence in HCT116 spheroids was recorded from equatorial sections in a confocal microscope (magnification, 200×). Within 3 d, the CAIX-overexpressing
spheroids (B) grew larger than the EV ones (A). (C) Staining of CAIX-overexpressing spheroids with both Var3 (red) and control peptide K-Var3 (blue) showed
that Var3 was retained within the spheroid, whereas K-Var3 was not taken up and remained outside.
Fig. 3. pHLIP uptake and retention is pH dependent. (A) Tumor growth curves of EV and CAIX-overexpressing HCT116 cells in nude mice. CAIX over-
expression enhanced tumor growth. (B) The uptake and retention of pHLIP Var3 in CAIX-overexpressing tumors (normalized to volume) was significantly
higher than in EV controls over time. (C) AZA treatment reduced pHLIP retention significantly within 24 h. Mice bearing 4T1 tumors were injected with pHLIP
and treated with AZA or left untreated. The mice were imaged at 1 h and 24 h postinjection, and the decline in fluorescence was calculated. The increase in
pH as effected by AZA accelerated the decrease in pHLIP fluorescence significantly (n = 4–6 per group; data are mean ± SEM).
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pHLIPs (24, 54). We show that manipulation of pH in spheroids
and in xenografts by the use of CAIX-positive and -negative
cancer cells leads to differential retention of pHLIP Var3, con-
sistent with more acidic extracellular pH. The tuning of pH by
AZA-mediated CAIX inhibition led to a significant decrease in
pHLIP Var3 retention in 4T1 tumors. In previous work we
showed that tumors from a variety of cancer types in mice retain
pHLIP peptides (24, 37, 54). Here we have used both models of
colorectal cancer and breast cancer. Thus, the retention of a
signal from pHLIP Var3 peptide indicates the presence of ex-
tracellular acidosis in murine tumor models, and likely in man.
We then asked whether such a biomarker might be used to
identify early neoplasia. Enhanced utilization of glycolytic me-
tabolism is a characteristic, indeed hallmark, of cancer, however
the time and extent of its induction during carcinogenesis are not
known. Hence we examined the retention of pHLIP Var3 in a
transgenic model of breast cancer. There was no evidence of
retention of pHLIP Var3 in normal breast tissue. These results
indicate that false-positives are uncommon in this model using
pHLIP Var3 as a marker. And all of the larger cancers retained
pHLIP Var3, indicative of acidic pH. Thus, detection of pHLIP
Var3 appears to be a good indicator of well-established malig-
nancy in this model as well. However, although most of the early
lesions retained the pHLIP signal, many did not. This raises the
intriguing possibility that lesions can be stratified based upon
their pHLIP uptake, reflecting the extent of metabolic reprog-
ramming in any given lesion. These results lead to the hypothesis
that lesions with more acid pH may be more likely to go on to
form progressive lesions. Although these experiments were done
using an Alexa Fluor-conjugated version of pHLIP Var3, future
studies in man could use single photon emission computed to-
mography (SPECT) or positron emission tomography (PET)
tracers to enable detection. Fluorescence could possibly be useful
for light imaging of dysplastic lesions of the gastrointestinal tract.
Tumor pH may display heterogeneous distribution, affecting the
overall signal; thus, pH imaging with higher spatial resolution
might be needed to address this potential issue.
It is clear in human breast cancer that many lesions that ap-
pear to be cancerous by pathological criteria may not actually
result in deleterious events for the patient. This is becoming
apparent from the disappointing limitations of mammography to
identify disease in patients that affects their long-term survival.
Mammography clearly can recognize lesions that are identified
by pathology as malignant. However, their removal has only a
limited improvement on long-term survival of the population
overall (55, 56). Our results now raise the question of whether
discrimination of lesional pH might add very valuable predictive
information. Further research to determine whether altered pH
in early neoplastic lesions correlates with biological behavior will
be required and would help to possibly establish pH-based strat-
ification of neoplastic lesions.
In conclusion, we believe that the pHLIPs, in general, and
pHLIP Var3, specifically—with its significantly reduced level of
false-positive signal—have the potential to be predictive markers
of tumor invasiveness and aggressiveness.
Materials and Methods
Synthesis of Fluorescent Constructs. The pHLIP variants were prepared by solid-
phase peptide synthesis using 9-fluorenylmethyloxycarbonyl chemistry and
purified by reverse phase chromatography by James I. Elliott at the W.M. Keck
Foundation Biotechnology Resources Laboratory at Yale University (New
Haven, CT). The concentration of fluorescent pHLIPs was determined by
absorbance using the molar extinction coefficient: e556 = 104,000 M
−1·cm−1
for Alexa546-pHLIPs and e650 = 239,000 M
−1·cm−1 for Alexa647-pHLIPs. All
pHLIP peptides (WT, Var3, Var7, K3, and K7) were dissolved in PBS pH 7.4
at a concentration of 40 μM. For in vivo experiments, pHLIP was injected i.v.
(40 μM/100 μL) or otherwise used as indicated.
Cells. All cells were grown in DMEM 10% (vol/vol) FCS with penicillin/
streptomycin at 37 °C, 5% (vol/vol) CO2. The 4T1 cells were from ATCC. The
HCT116 and variants thereof were used as described previously (8).
Fluorescent pHLIP Uptake by Tumor Spheroids. Spheroids were grown on
agarose beds (1%) in tissue culture plates. Briefly, 104 cells were seeded onto
an agarose bed within a 24-well plate cavity and left to grow for 3 d at 37 °C,
5% (vol/vol) CO2. The resulting spheroid was removed from the cavity and
incubated with pHLIP for 6 h, then washed twice with PBS, and recorded by
z-stack in a confocal microscope (Zeiss 710 LSM).
AZA. AZA (Sigma) was dissolved in 0.9% sodium chloride/1% DMSO for i.v.
injection at 45 mg/kg as described before (49).
Animals.Mice were used in accordance with the Animals Scientific Procedures
Act of 1986 and local ethical guidelines at the University of Oxford following
approval by the local Clinical Medicine Ethical Review Committee. Female
BALB/c mice and BALB/c nude mice were purchased at 8 wk of age from
Fig. 5. pHLIP Var3 detects spontaneously arising tumors in vivo. BALB/neu-T
mice of different ages and therefore at different stages of tumor de-
velopment were injected with pHLIP Var3. To measure the fluorescent signal
from the tumors, mice were killed and the mammary glands/tumors were
exposed (A). Late stage malignancies were highlighted by marked pHLIP
uptake (c and d), whereas other regions in earlier stages of development in
some cases were marked and in some cases were not marked (a and b). A
total of 164 samples were taken and analyzed. (B) An example of a tumor
showing invasive carcinoma (C) and carcinoma in situ (D).
Fig. 4. The pH was measured in BALB/neu-T tumors in vivo. To demonstrate
the feasibility of in vivo pH measurement, tumor-bearing BALB/neu-T mice
were used in a 9.4T MRI tuned to the 31P signal. To avoid contamination of
the voxel measured, ISIS was used to specify the area of measurement. No
fluorescence signal above background (FL/BKG) was detected from muscle,
whereas the tumor showed a signal-to-noise ratio of ∼2.5. At the same time,
the tumor showed a lower pH of 6.7 ± 0.0 than the muscle, 7.1 ± 0.1 (n = 3 in
both groups; data are mean ± SEM).











Charles River. BALB/neu-T mice (48) were bred by the biomedical services
unit in Oxford.
In Vivo and Ex Vivo Animal Imaging. For in vivo measurements, animals were
anesthetized and placed in an in vivo imaging system (IVIS; Xenogen).
Alexa546 fluorescence was read (excitation, 500–550 nm; emission detec-
ted between 575 and 650 nm) and compared with a reading of back-
ground fluorescence, which was subtracted (Living Image software V3.2).
The result was used to measure region of interest (ROI) fluorescence from
the tumors. To visualize mammary glands in BALB/neu-T mice, mice were
killed following pHLIP injection, the skin was removed, and tumors imaged
in the IVIS. Mammary glands were harvested and one half snap-frozen in
liquid nitrogen and the other half fixed in formalin for pathological
evaluation.
Histopathology. Formalin-fixed paraffine-embedded samples were cut and
stained with H&E. The samples were then graded by a pathologist blind to
the experimental groups.
31P MRS Measurement of pH in Vivo. MRS was performed on a 9.4 T 160 mm
VNMRS horizontal bore preclinical imaging system equipped with a 100 mm
bore gradient insert capable of 400 mT/m (Varian, Inc.). Radio frequency (RF)
transmission was performedwith an actively decoupled 35mm ID quadrature
birdcage coil (Rapid Biomedical GmbH). RF reception was performed with
a custom-made actively decoupled 15 mm surface coil. 31P localization
was performed with image-selected in vivo spectroscopy (ISIS) (57) using
adiabatic hyperbolic secant inversion pulses with a bandwidth of 15 kHz in
combination with outer voxel suppression. 31P ISIS spectra from voxels (125–
180 mm3) placed within tumors were acquired with 1,024 averages from
tumors and 256 averages from muscle and repetition time (TR) of 3 s. In the
absence of detectable PCr signal, the α-ATP signal at −7.52 ppm was used as
a chemical shift reference, as the α-ATP signal shift is virtually the same as
that of the PCr signal in the pH range of 6–8 (58). Intracellular pH was cal-
culated according to the chemical shift of the Pi signal using a modified
Henderson–Hasselbach relationship with pK = 6.77, which represents aver-
age literature values (59).
Statistical Analysis. Unless stated otherwise, data are expressed as means ±
SEM and were analyzed using the Mann–Whitney test for comparisons be-
tween two groups of animals and one-way ANOVA for more than two groups.
P values lower than 0.05 were assumed to express a significant difference (*P <
0.05, **P < 0.01, ***P < 0.001).
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